Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 4/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 10/20 | 0.39 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2528392 | 0.95 | NAAA (0.43) | TP53ADORA1NAAAALDH1A1SMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL563520 | 0.91 | TP53 (0.38) | TP53ADORA1ALDH1A1SMN1; SMN2KDM4E | |
| Trifluoroacetic Acid SCHEMBL562338 | 0.91 | TP53 (0.38) | TP53ADORA1ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL563194 | 0.89 | ADORA1 (0.47) | TP53ADORA1NAAAALDH1A1SMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL562581 | 0.89 | TP53 (0.33) | TP53ADORA1ALDH1A1ADORA3SMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL562279 | 0.88 | TP53 (0.37) | TP53ADORA1ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL562537 | 0.87 | TP53 (0.43) | TP53ADORA1ALDH1A1KDM4EMEN1 | |
| SCHEMBL2523024 | 0.85 | TP53 (0.40) | TP53ADORA1ALDH1A1SMN1; SMN2MEN1 | |
| Trifluoroacetic Acid SCHEMBL562126 | 0.85 | RXFP1 (0.40) | TP53ALDH1A1SMN1; SMN2KDM4ENPSR1 | |
| Trifluoroacetic Acid SCHEMBL562497 | 0.85 | ALDH1A1 (0.38) | ADORA1ALDH1A1ADORA3SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140371216-A1 | PURINONE DERIVATIVES AS HM74A AGONISTS | INCYTE CORPORATION (US) | 2014-12-18 | — | — | US | disclosed |
| US-8703783-B2 | Purinone derivatives as HM74A agonists | INCYTE CORPORATION (US) | 2014-04-22 | — | — | US | disclosed |
| US-20120035172-A1 | Purinone Derivatives as HM74A Agonists | INCYTE CORPORATION (US) | 2012-02-09 | — | — | US | disclosed |
| US-8039478-B2 | Purinone derivatives as HM74A agonists | INCYTE CORPORATION (US) | 2011-10-18 | — | — | US | disclosed |
| US-20090286774-A1 | PURINONE DERIVATIVES AS HM74A AGONISTS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
| EP-2044074-A2 | PURINONE DERIVATIVES AS HM74A AGONISTS | Incyte Corporation (US) | 2009-04-08 | — | — | EP | disclosed |
| US-7511050-B2 | hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors; avoiding adverse effects such as hepatotoxicity and cutaneous flushing; low dosage; 2-bromo-8-methyl-4-pentyl-1,4-dihydro-5H-[1,2,4]triazolo[5,1-i]purin-5-one; to treat cardiovascular disorders | INCYTE CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| US-20080045554-A1 | hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors; avoiding adverse effects such as hepatotoxicity and cutaneous flushing; low dosage; 2-bromo-8-methyl-4-pentyl-1,4-dihydro-5H-[1,2,4]triazolo[5,1-i]purin-5-one; to treat cardiovascular disorders | INCYTE CORPORATION (US) | 2008-02-21 | — | — | US | disclosed |
| WO-2007150025-A2 | PURINONE DERIVATIVES AS HM74A AGONISTS | INCYTE CORPORATION (US) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371216-A1 | PURINONE DERIVATIVES AS HM74A AGONISTS | GPR84, P2RY1, ADRA1A | TP53 2735/4885ADORA1 39/4885NAAA 707/4885 |
| US-20120035172-A1 | Purinone Derivatives as HM74A Agonists | GPR84, P2RY1, ADRA1A | TP53 2735/4885ADORA1 39/4885NAAA 707/4885 |
| US-20090286774-A1 | PURINONE DERIVATIVES AS HM74A AGONISTS | GPR84, P2RY1, ADRA1A | TP53 2735/4885ADORA1 39/4885NAAA 707/4885 |
| US-20080045554-A1 | hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors; avoiding adverse effects such as hepatotoxicity and cutaneous flushing; low dosage; 2-bromo-8-methyl-4-pentyl-1,4-dihydro-5H-[1,2,4]triazolo[5,1-i]purin-5-one; to treat cardiovascular disorders | HMGCR, LDLR, GPBAR1 | TP53 3114/4885ADORA1 50/4885NAAA 2347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.